OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Florez on the Significance of a Consensus Manuscript From the BTG Lung Cancer Conference

September 4th 2025

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

Dr Diaz on the Importance of Early Recognition for Optimal Uterine Cancer Management

September 4th 2025

John P. Diaz, MD, discusses the importance of uterine cancer recognition and treatment optimization in the context of Gynecologic Cancer Awareness Month.

Dr Kahn on Recognizing Surgical Limitations in Advanced Ovarian Cancer During Ovarian Cancer Awareness Month

September 4th 2025

Ryan Matthew Kahn, MD, MHS, FACOG, discusses the importance of recognizing surgical limitations in the treatment of patients with advanced ovarian cancer.

Dr McArthur on Data Supporting the Ongoing Investigation of Palazestrant in ER+, HER2– Breast Cancer

September 3rd 2025

Heather McArthur, MD, MPH, FASCO, discusses data from a phase 1/2 study evaluating palazestrant in ER+, HER2– advanced or metastatic breast cancer.

Dr Cortes on the Evolving Treatment Paradigm for Leukemia and Lymphoma

September 3rd 2025

Jorge Cortes, MD, discusses the state of the leukemia and lymphoma treatment paradigms in 2025 in recognition of Leukemia and Lymphoma Awareness Month

Dr Shameem on Selecting NALIRIFOX vs FOLFIRINOX in Advanced Pancreatic Cancer

September 3rd 2025

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.

Dr Klempner on the Safety Profile of Givastomig Plus Nivolumab and mFOLFOX6 in Gastric, Esophageal, and GEJ Cancer

September 3rd 2025

Samuel J. Klempner, MD, details the safety profile of givastomig/nivolumab and mFOLFOX6 in CLDN18.2-positive gastric, esophageal, and GEJ cancers.

Dr Aldoss on MRD Negativity Outcomes With Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

September 3rd 2025

Ibrahim T. Aldoss, MD, discusses MRD negativity outcomes with ponatinib vs imatinib in newly diagnosed Philadelphia chromosome–positive ALL.

Dr Wong on Next Steps for Validating the Predictive Utility of Molecular Characteristics in CRC

September 2nd 2025

Evelyn Y.T. Wong, MD, discusses discussed the potential use of molecular characteristics to predict survival outcomes in early-onset CRC.

Dr Van Tine on Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

September 2nd 2025

Brian A. Van Tine, MD, PhD, discussed trial findings with olaparib plus temozolomide in advanced uterine leiomyosarcoma following prior chemotherapy.

Dr Tarhini on the Rationale for Studying Vidutolimod Plus Pembrolizumab in Melanoma

September 2nd 2025

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

Dr Élez on Health-Related QOL With Nivolumab Plus Ipilimumab in mCRC

September 2nd 2025

Elena Élez, MD, PhD, discusses health-related QOL data with nivolumab plus ipilimumab in mCRC.

Dr Olmos on the Prognostic Implications of Data From the CAPTURE Study for BRCA-Mutant mHSPC

September 2nd 2025

David Olmos, MD, PhD, discusses the implications of data from the CAPTURE study for risk stratification in mHSPC harboring BRCA mutations.

Dr Haas on the Rationale for Evaluating Adjuvant Pembrolizumab in Clear Cell RCC

September 2nd 2025

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Dr Raza on Unmet Needs in R/R Myeloma With Extramedullary Disease

September 2nd 2025

Shahzad Raza, MD, highlights the challenges associated with managing relapsed/refractory multiple myeloma with extramedullary disease.

Dr Schlechter on the Potential Future Implications of Botensilimab and Balstilimab in MSS mCRC

September 2nd 2025

Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.

Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBC

August 29th 2025

Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.

Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC

August 29th 2025

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Diagnosed Myeloma

August 29th 2025

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Dr Khan on the Development of Second-Generation BTK Inhibitors in CLL

August 29th 2025

Cyrus M. Khan, MD, detailed the development of second-generation BTK inhibitors and how they compare with first-generation BTK inhibitors in CLL.